A Trial of Setmelanotide in Acquired Hypothalamic Obesity
Status:
Recruiting
Trial end date:
2025-04-16
Target enrollment:
Participant gender:
Summary
The goal of this trial is to learn how well Setmelanotide works to improve weight reduction,
hunger, and quality of life in patients 4 years of age and older with acquired Hypothalamic
Obesity (HO). To determine how well setmelanotide works and how safe it is, patients with HO
will take a daily injection of either setmelanotide or placebo and complete trial assessments
for up to 60 weeks.